Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-31false2024-01-01medical supplies00truetruefalse 07475277 2024-01-01 2024-12-31 07475277 2023-01-01 2023-12-31 07475277 2024-12-31 07475277 2023-12-31 07475277 2023-01-01 07475277 c:Director1 2024-01-01 2024-12-31 07475277 d:PlantMachinery 2024-01-01 2024-12-31 07475277 d:PlantMachinery 2024-12-31 07475277 d:PlantMachinery 2023-12-31 07475277 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 07475277 d:FurnitureFittings 2024-01-01 2024-12-31 07475277 d:FurnitureFittings 2024-12-31 07475277 d:FurnitureFittings 2023-12-31 07475277 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 07475277 d:OfficeEquipment 2024-01-01 2024-12-31 07475277 d:OfficeEquipment 2024-12-31 07475277 d:OfficeEquipment 2023-12-31 07475277 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 07475277 d:ComputerEquipment 2024-01-01 2024-12-31 07475277 d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 07475277 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-01-01 2024-12-31 07475277 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-12-31 07475277 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-12-31 07475277 d:Goodwill 2024-01-01 2024-12-31 07475277 d:Goodwill 2024-12-31 07475277 d:Goodwill 2023-12-31 07475277 d:ComputerSoftware 2024-01-01 2024-12-31 07475277 d:ComputerSoftware 2024-12-31 07475277 d:ComputerSoftware 2023-12-31 07475277 d:OtherResidualIntangibleAssets 2024-01-01 2024-12-31 07475277 d:CurrentFinancialInstruments 2024-12-31 07475277 d:CurrentFinancialInstruments 2023-12-31 07475277 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 07475277 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 07475277 d:ShareCapital 2024-01-01 2024-12-31 07475277 d:ShareCapital 2024-12-31 07475277 d:ShareCapital 2023-01-01 2023-12-31 07475277 d:ShareCapital 2023-12-31 07475277 d:ShareCapital 2023-01-01 07475277 d:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 07475277 d:RetainedEarningsAccumulatedLosses 2024-12-31 07475277 d:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 07475277 d:RetainedEarningsAccumulatedLosses 2023-12-31 07475277 d:RetainedEarningsAccumulatedLosses 2023-01-01 07475277 d:AcceleratedTaxDepreciationDeferredTax 2024-12-31 07475277 d:AcceleratedTaxDepreciationDeferredTax 2023-12-31 07475277 d:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2024-01-01 2024-12-31 07475277 d:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2024-12-31 07475277 c:FRS102 2024-01-01 2024-12-31 07475277 c:Audited 2024-01-01 2024-12-31 07475277 c:FullAccounts 2024-01-01 2024-12-31 07475277 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 07475277 c:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 07475277 d:Goodwill d:OwnedIntangibleAssets 2024-01-01 2024-12-31 07475277 d:DevelopmentCostsCapitalisedDevelopmentExpenditure d:OwnedIntangibleAssets 2024-01-01 2024-12-31 07475277 d:ComputerSoftware d:OwnedIntangibleAssets 2024-01-01 2024-12-31 07475277 e:PoundSterling 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure

Registered number: 07475277









SANKEY HEALTH LIMITED









FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

 
SANKEY HEALTH LIMITED
REGISTERED NUMBER: 07475277

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2024

2024
2023
Note
£
£

Fixed assets
  

Intangible assets
 5 
-
165,940

Tangible assets
 6 
-
137,282

  
-
303,222

Current assets
  

Stocks
  
37,802
171,734

Debtors: amounts falling due within one year
 7 
1,378,121
1,203,128

Cash at bank and in hand
 8 
200
69,498

  
1,416,123
1,444,360

Creditors: amounts falling due within one year
 9 
(2,529,599)
(2,933,689)

Net current liabilities
  
 
 
(1,113,476)
 
 
(1,489,329)

Total assets less current liabilities
  
(1,113,476)
(1,186,107)

Provisions for liabilities
  

Deferred tax
 10 
-
(32,147)

Other provisions
 11 
(424,130)
-

  
 
 
(424,130)
 
 
(32,147)

Net liabilities
  
(1,537,606)
(1,218,254)


Capital and reserves
  

Called up share capital 
  
1
1

Profit and loss account
  
(1,537,607)
(1,218,255)

  
(1,537,606)
(1,218,254)


The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 25 September 2025.

Page 1

 
SANKEY HEALTH LIMITED
REGISTERED NUMBER: 07475277
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2024

A Bones
Director

The notes on pages 5 to 13 form part of these financial statements.

Page 2

 
SANKEY HEALTH LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024


Called up share capital
Profit and loss account
Total equity

£
£
£

At 1 January 2024
1
(1,218,255)
(1,218,254)


Comprehensive income for the year

Loss for the year

-
(319,352)
(319,352)


Other comprehensive income for the year
-
-
-


Total comprehensive income for the year
-
(319,352)
(319,352)


Total transactions with owners
-
-
-


At 31 December 2024
1
(1,537,607)
(1,537,606)


The notes on pages 5 to 13 form part of these financial statements.

Page 3

 
SANKEY HEALTH LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2023


Called up share capital
Profit and loss account
Total equity

£
£
£

At 1 January 2023
1
(3,393,752)
(3,393,751)


Comprehensive income for the year

Profit for the year

-
2,175,497
2,175,497


Other comprehensive income for the year
-
-
-


Total comprehensive income for the year
-
2,175,497
2,175,497


Total transactions with owners
-
-
-


At 31 December 2023
1
(1,218,255)
(1,218,254)


The notes on pages 5 to 13 form part of these financial statements.

Page 4

 
SANKEY HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1.


General information

Sankey Health Limited is a private company limited by shares incorporated in England and Wales. The registered office is 9 Lakeside Drive (also known as 820 Mandarin Court), Centre Park, Warrington, England, WA1 1GG

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 3).

The following principal accounting policies have been applied:

 
2.2

Going concern

Not withstanding the current year loss after tax of £319,352 and net liabilities of £1,537,606, at the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. This is due to the restructure and a more focused approach with the wellness and fitness product division. The directors have also received confirmation of ongoing support from its ultimate parent company, PAM Healthcare Limited. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

Page 5

 
SANKEY HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.4

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

Page 6

 
SANKEY HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.5

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


 
2.6

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 The estimated useful lives range as follows:

Software
-
3
years
Customer List
-
10
years

 
2.7

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

At each reporting date the Company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

Page 7

 
SANKEY HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)


2.7
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Plant and machinery
-
20%
straight line
Fixtures and fittings
-
20%
straight line
Computer equipment
-
33%
reducing balance

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.8

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.9

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.10

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.11

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 8

 
SANKEY HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.12

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.


3.


Judgments in applying accounting policies and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
Critical judgements and estimates
The following judgements and estimates have had the most significant effect on amounts recognised in the financial statements.
Carrying value of stock
The directors have reviewed the stock the company is carrying against the plans of the business and have determined that items considered slow moving require a provision against them based on discounted sales prices required to sell the stock. The carrying value of the stock at 31 December 2024 is £37,802 (2023: £171,734).


4.


Employees

The Company has no employees other than the directors, who did not receive any remuneration (2023 - £NIL).

Page 9

 
SANKEY HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

5.


Intangible assets




Customer List
Computer software
Goodwill
Total

£
£
£
£





At 1 January 2024
25,000
381,140
188,250
594,390


Disposals
(25,000)
(381,140)
(188,250)
(594,390)



At 31 December 2024

-
-
-
-





At 1 January 2024
-
240,200
188,250
428,450


Charge for the year on owned assets
-
91,106
-
91,106


On disposals
-
(331,306)
(188,250)
(519,556)



At 31 December 2024

-
-
-
-



Net book value



At 31 December 2024
-
-
-
-



At 31 December 2023
25,000
140,940
-
165,940



Page 10

 
SANKEY HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

6.


Tangible fixed assets





Plant and machinery
Fixtures and fittings
Office equipment
Total

£
£
£
£





At 1 January 2024
67,931
347,500
2,186
417,617


Additions
-
47,694
-
47,694


Disposals
(67,931)
(395,194)
(2,186)
(465,311)



At 31 December 2024

-
-
-
-





At 1 January 2024
50,730
228,548
1,056
280,334


Charge for the year on owned assets
12,203
94,507
1,039
107,749


Disposals
(62,933)
(323,055)
(2,095)
(388,083)



At 31 December 2024

-
-
-
-



Net book value



At 31 December 2024
-
-
-
-



At 31 December 2023
17,201
118,952
1,130
137,283

Page 11

 
SANKEY HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

7.


Debtors

2024
2022
£
£


Trade debtors
183,368
324,846

Amounts owed by group undertakings
1,018,044
814,232

Other debtors
147,956
27,830

Prepayments and accrued income
26,832
36,220

Deferred taxation
1,921
-

1,378,121
1,203,128



8.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
200
69,498

Less: company credit card
(14,966)
-

(14,766)
69,498



9.


Creditors: Amounts falling due within one year

2024
2023
£
£

Company credit card
14,966
-

Trade creditors
89,821
48,559

Amounts owed to group undertakings
2,315,459
2,801,496

Other taxation and social security
39,052
55,685

Other creditors
2,275
4,003

Accruals and deferred income
68,026
23,946

2,529,599
2,933,689


LDC (Managers) Limited hold a fixed and and floating charge over the assets of company dated 25 June 2021.
HSBC UK Bank Plc hold a fixed and floating charge over the assets of the company dated 11 October 2016.

Page 12

 
SANKEY HEALTH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

10.


Deferred taxation




2024


£






At beginning of year
(32,147)


Charged to profit or loss
34,068



At end of year
1,921

The deferred taxation balance is made up as follows:

2024
2023
£
£


Accelerated capital allowances
1,921
(32,147)

1,921
(32,147)


11.


Provisions




Onerous lease provision

£





Charged to profit or loss
424,130



At 31 December 2024
424,130


12.


Controlling party

People Asset Management Group Limited is the immediate parent company. PAM Healthcare Limited is the ultimate parent company and the largest and smallest group in which Sankey Health Limited is a member and for which consolidated financial statements are prepared and publicly available. A copy of the group financial statements can be obtained from PAM Healthcare Limited, 9 Lakeside Drive (Also Known As 820 Mandarin Court), Centre Park, Warrington, England, WA1 1GG.


13.


Auditors' information

The auditors' report on the financial statements for the year ended 31 December 2024 was unqualified.

The audit report was signed on 26 September 2025 by Chris Speakman FCCA (Senior statutory auditor) on behalf of WR Partners.

Page 13